search
Back to results

A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis

Primary Purpose

Tinea Pedis

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Oxiconazole Nitrate Cream 1%
Oxiconazole Nitrate Cream 1% (Oxistat®)
Placebo
Sponsored by
Taro Pharmaceuticals USA
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tinea Pedis focused on measuring Tinea Pedis

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or non-pregnant, non-lactating female, 12 years of age or older.
  2. Signed informed consent form, which meets all criteria of current FDA regulations
  3. If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study {e.g., condom, IUD, oral, transdermal, injected or implanted hormonal contraceptives)and (must have used the same product for at least 30 days prior to the study start and use the same product throughout the duration of the study), transdermal or implanted hormonal contraceptives}
  4. A confirmed clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot. (the non-interdigital lesions should not be hyperkeratotic i.e., characteristic of moccasin).
  5. The presence of tinea pedis infection, confirm by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Exclusion Criteria:

  1. Females who are pregnant, or lactating or likely to become pregnant during the study.
  2. Any known hypersensitivity to oxiconazole nitrate or other antifungal agents.
  3. Patients with a past history of tinea pedis infections with a lack of response to antifungal therapy (i.e. recurrent tinea pedis, more than 3 infections in the past 12 months, which were unresponsive to previous antifungal therapy).
  4. Participation in a research study in the past 30 days prior to screening/randomization.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Active Comparator

    Placebo Comparator

    Arm Label

    Oxiconazole Nitrate Cream 1%

    Oxiconazole Nitrate Cream 1% (Oxistat®)

    Placebo

    Arm Description

    Outcomes

    Primary Outcome Measures

    Therapeutic Cure
    Clinical & Mycological Cure at 6 weeks

    Secondary Outcome Measures

    Clinical Cure
    Proportion of patients considered a clinical cure at 6 weeks
    Mycological Cure
    Proportion of patients with both KOH & culture negative at 6 weeks

    Full Information

    First Posted
    January 19, 2012
    Last Updated
    January 19, 2014
    Sponsor
    Taro Pharmaceuticals USA
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01519752
    Brief Title
    A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
    Official Title
    A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site, Study Comparing Oxiconazole Nitrate Cream 1% (Taro Pharmaceuticals,Inc) to Oxistat® (Oxiconazole Nitrate Cream) Cream 1% (PharmaDerma) in the Treatment of Tinea Pedis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2011 (undefined)
    Primary Completion Date
    August 2012 (Actual)
    Study Completion Date
    November 2012 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Taro Pharmaceuticals USA

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The objective of this study is to demonstrate that Oxiconazole nitrate 1% topical cream is effective for the treatment of patients with moderate to severe Tinea pedis.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Tinea Pedis
    Keywords
    Tinea Pedis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    661 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Oxiconazole Nitrate Cream 1%
    Arm Type
    Experimental
    Arm Title
    Oxiconazole Nitrate Cream 1% (Oxistat®)
    Arm Type
    Active Comparator
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Oxiconazole Nitrate Cream 1%
    Intervention Description
    Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
    Intervention Type
    Drug
    Intervention Name(s)
    Oxiconazole Nitrate Cream 1% (Oxistat®)
    Intervention Description
    Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    Placebo applied to affected area once a day for 28 days
    Primary Outcome Measure Information:
    Title
    Therapeutic Cure
    Description
    Clinical & Mycological Cure at 6 weeks
    Time Frame
    Day 42
    Secondary Outcome Measure Information:
    Title
    Clinical Cure
    Description
    Proportion of patients considered a clinical cure at 6 weeks
    Time Frame
    Day 42
    Title
    Mycological Cure
    Description
    Proportion of patients with both KOH & culture negative at 6 weeks
    Time Frame
    Day 42

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    12 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or non-pregnant, non-lactating female, 12 years of age or older. Signed informed consent form, which meets all criteria of current FDA regulations If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study {e.g., condom, IUD, oral, transdermal, injected or implanted hormonal contraceptives)and (must have used the same product for at least 30 days prior to the study start and use the same product throughout the duration of the study), transdermal or implanted hormonal contraceptives} A confirmed clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot. (the non-interdigital lesions should not be hyperkeratotic i.e., characteristic of moccasin). The presence of tinea pedis infection, confirm by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination. Exclusion Criteria: Females who are pregnant, or lactating or likely to become pregnant during the study. Any known hypersensitivity to oxiconazole nitrate or other antifungal agents. Patients with a past history of tinea pedis infections with a lack of response to antifungal therapy (i.e. recurrent tinea pedis, more than 3 infections in the past 12 months, which were unresponsive to previous antifungal therapy). Participation in a research study in the past 30 days prior to screening/randomization.

    12. IPD Sharing Statement

    Learn more about this trial

    A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis

    We'll reach out to this number within 24 hrs